MIPS #450 Appropriate Treatment for Patients with Stage I (T1c) - III HER2 Positive Breast Cancer
2026 measure specification review pending.
2025 measure specifications changes from 2024 highlighted below. Practice Insights coding changes completed for 2025
Practice Insights 2025 coding changes completed 5/27/25
MEASURE DESCRIPTION
Percentage of patients aged 18 to 70 with stage I (T1c) – III HER2 positive breast cancer for whom appropriate treatment is initiated.
Relevance to Value Based Care
Clinical studies have shown that the administration of Trastuzumab or biosimilar significantly improves overall survival in patients with high-risk HER2 positive breast cancer.
Numerator
Patients whose adjuvant treatment course includes both chemotherapy and HER2-targeted therapy
Denominator
Female All breast cancer patients aged 18 to 70 with pathologic stage I (T1c) – III HER2 positive breast cancer diagnosed between July 1st of the previous performance period through June 30th of the current performance period-
Exclusion/Exceptions
Pregnancy
Inbound after initiation of treatment
Medical or patient reason for not administering HER2-targeted therapy
Telehealth included: No
Scoring Up to 6 points, unless 100% = 10 points
